

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8105856

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
I-MAB BIOPHARMA US LIMITED	04/13/2023
RECEIVING PARTY DATA	
Name:	I-MAB BIOPHARMA CO., LTD.
Street Address:	RM802, 8F, 1BLD., WEST TOWER
Internal Address:	88 SHANGKE ROAD., PUDONG
City:	SHANGHAI
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16989702
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	wtokmakidis@jonesday.com, dtran@jonesday.com, jianlewang@jonesday.com, melissahe@jonesday.com, bliang@jonesday.com
Correspondent Name:	JONES DAY
Address Line 1:	250 VESEY STREET
Address Line 2:	ATTN: WENDY TOKMAKIDIS
Address Line 4:	NEW YORK, NEW YORK 10281
ATTORNEY DOCKET NUMBER:	13371-226-999
NAME OF SUBMITTER:	DAI TRAN
SIGNATURE:	/Dai Tran/
DATE SIGNED:	08/09/2023
Total Attachments: 6	
source=13371-226-999_Executed_Assignments_I-Mab_US_to_I-Mab_SH#page1.tif	
source=13371-226-999_Executed_Assignments_I-Mab_US_to_I-Mab_SH#page2.tif	
source=13371-226-999_Executed_Assignments_I-Mab_US_to_I-Mab_SH#page3.tif	
source=13371-226-999_Executed_Assignments_I-Mab_US_to_I-Mab_SH#page4.tif	
source=13371-226-999_Executed_Assignments_I-Mab_US_to_I-Mab_SH#page5.tif	

ASSIGNMENT

This Assignment is by:

Assignor: I-Mab Biopharma US Limited
Address: 9801 Washingtonian Blvd.
Suite 710
Gaithersburg, Maryland 20878
A juristic entity duly organized under and pursuant to the laws of: California

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the patents and patent applications listed on Exhibit A attached hereto (collectively, the "Patents").

This Assignment is to:

Assignee: I-Mab Biopharma Co., Ltd. (天境生物科技(上海)有限公司)
Address: Rm802, 8F, 1Bld., West Tower,
88 Shangke Rd., Pudong,
Shanghai, China
A juristic entity duly organized under and pursuant to the laws of: China

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the Patents and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement:

1. Assignor hereby sells, assigns, transfers and sets over to Assignee Assignor's entire right, title and interest in and to the Patents, for the United States and foreign countries or jurisdictions (and corresponding inventions), and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of any applications contained in the Patents, and any and all letters patent or patents in the United States and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and enjoyment, and for the use and enjoyment of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made, together with all income, royalties, damages or payments due or payable as of the date of this Assignment or thereafter, and any and all rights to claim priority to the applications contained in the Patents and any and all applications claiming priority thereto or based on said inventions, including, without limitation, all claims for damages by reason of past, present or future infringement or other authorized use of the Patents, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, legal representatives and assigns.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States and the corresponding entities or agencies in any applicable foreign countries, to record Assignee as the assignee and owner of the Patents.

3. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: Apr 13, 2023

Signature: _____

Name: ~~Zhang Jingwu Zhang~~
Title: Director
Company: I-Mab Biopharma US Limited

ASSIGNEE:

Date: Apr 13, 2023

Signature: _____

Name: Andrew Xiuxuan Zhu
Title: Legal Representative
Company: I-Mab Biopharma Co., Ltd.

EXHIBIT A

The patents and patent applications that are being assigned from **I-Mab Biopharma US Limited to I-Mab Biopharma Co., Ltd.** are:

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
Patent Cooperation Treaty	PCT/CN2016/102720	Oct-20-2016			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Patent Cooperation Treaty	PCT/CN2017/076462	Mar-13-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Patent Cooperation Treaty	PCT/CN2017/000329	Apr-24-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Hong Kong	19122494.8	Apr-17-2019			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Canada	2,999,058	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Australia	2017332960	Oct-20-2017	2017332960	Jan-02-2020	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
New Zealand	752255	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Mexico	MX/a/2019/004691	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Chile	2019-01088	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Peru	000860-2019/DIN	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Japan	2018-519859	Oct-20-2017	7043074	Mar-18-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Colombia	NC2019/0005033	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Brazil	BR 11 2019 008010 4	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Singapore	11201903514V	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
India	201917016128	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Indonesia	PID201904003	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Philippines	1-2019-500862	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
South Africa	2019/02118	Oct-20-2017	2019/02118	Apr-28-2021	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Israel	258352	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
Republic of Korea	10-2018-7010559	Oct-20-2017	10-2136742	Jul-16-2020	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Eurasian Patent Organization	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
European Patent Office	17849891.1	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Patent Cooperation Treaty	PCT/US2017/057535	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Malaysia	PI 2019002154	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Belarus	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Ukraine	a201905223	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Kazakhstan	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Azerbaijan	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Armenia	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Kyrgyzstan	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Tajikistan	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Turkmenistan	201990764	Oct-20-2017	041310	Oct-06-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
United States of America	15/761,309	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Australia	2019222870	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
New Zealand	781739	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Japan	2022-035942	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Indonesia	P0020210810	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Israel	290412	Oct-20-2017	290412	Feb-02-2023	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Republic of Korea	10-2020-7020714	Oct-20-2017	10-2423086	Jul-15-2022	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
European Patent Office	22182052.5	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
United States of America	16/989,670	Aug-10-2020			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Australia	2020217349	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Republic of Korea	10-2022-7024524	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
United States of America	16/989,702	Aug-10-2020			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Patent Cooperation Treaty	PCT/CN2018/113126	Oct-31-2018			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Canada	3,107,369	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Australia	2019877886	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
New Zealand	775434	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Mexico	MX/a/2021/004779	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Japan	2021-506700	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Brazil	BR 11 2021 008332 4	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Singapore	11202104301S	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
India	202117019305	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
China	201980009759.7	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
South Africa	2021/02773	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Israel	280225	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Republic of Korea	10-2021-7005275	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Eurasian Patent Organization	202190900	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
European Patent Office	19877886.2	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Patent Cooperation Treaty	PCT/CN2019/114662	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
United States of America	17/257,294	Oct-31-2019			NOVEL CD47 ANTIBODIES AND METHODS OF USING SAME
Patent Cooperation Treaty	PCT/CN2020/088226	Apr-30-2020			PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
Japan	2022-565654	Apr-29-2021			PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
European Patent Office	21796475.8	Apr-29-2021			PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
Patent Cooperation Treaty	PCT/CN2021/091103	Apr-29-2021			PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
Patent Cooperation Treaty	PCT/CN2020/122159	Oct-20-2020			NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF
Patent Cooperation Treaty	PCT/CN2020/122188	Oct-20-2020			NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF
Taiwan	110138242	Oct-14-2021			
Patent Cooperation Treaty	PCT/CN2021/0123892	Oct-14-2021			
Australia	2021203783	Oct-20-2017			NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF
Japan	JP 2023-060732	Apr-5-2023			
Taiwan	110138243	Oct-14-2021			METHODS FOR MITIGATING INTERFERENCE BY THERAPEUTIC ANTI-CD47 ANTIBODIES IN PRE-TRANSFUSION ASSAYS
United States of America	17/997,522	Oct-28-2022			

sf-5533019